|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 August 2001, Vol. 98, No. 4, pp. 988-994
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Multidrug-resistance phenotype and clinical responses to
gemtuzumab ozogamicin
Michael L. Linenberger,
Tom Hong,
David Flowers,
Eric L. Sievers,
Ted A. Gooley,
John M. Bennett,
Mark S. Berger,
Lance H. Leopold,
Frederick R. Appelbaum, and
Irwin D. Bernstein
From the Clinical Research Division, Fred Hutchinson
Cancer Research Center; Departments of Medicine and Pediatrics,
University of Washington; both of Seattle, WA; University of Rochester
Medical Center, NY; and Wyeth-Ayerst Research, Radnor, PA.
Expression of multidrug resistance (MDR) features by acute myeloid
leukemia (AML) cells predicts a poor response to many treatments. The
MDR phenotype often correlates with expression of P-glycoprotein (Pgp),
and Pgp antagonists such as cyclosporine (CSA) have been used as
chemosensitizing agents in AML. Gemtuzumab ozogamicin, an
immunoconjugate of an anti-CD33 antibody linked to calicheamicin, is
effective monotherapy for CD33+ relapsed AML. However, the
contribution of Pgp to gemtuzumab ozogamicin resistance is poorly
defined. In this study, blast cell samples from relapsed AML patients
eligible for gemtuzumab ozogamicin clinical trials were assayed for Pgp
surface expression and Pgp function using a dye efflux assay. In most
cases, surface expression of Pgp correlated with Pgp function, as
indicated by elevated dye efflux that was inhibited by CSA. Among
samples from patients who either failed to clear marrow blasts or
failed to achieve remission, 72% or 52%, respectively, exhibited
CSA-sensitive dye efflux compared with 29% (P = .003) or
24% (P < .001) among samples from responders. In vitro
gemtuzumab ozogamicin-induced apoptosis was also evaluated using an
annexin V-based assay. Low levels of drug-induced apoptosis were
associated with CSA-sensitive dye efflux, whereas higher levels
correlated strongly with achievement of remission and marrow blast
clearance. In vitro drug-induced apoptosis could be increased by CSA in
14 (29%) of 49 samples exhibiting low apoptosis in the absence of CSA.
Together, these findings indicate that Pgp plays a role in clinical
resistance to gemtuzumab ozogamicin and suggest that treatment trials
combining gemtuzumab ozogamicin with MDR reversal agents are warranted.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. B. Walter, T. A. Gooley, V. H. J. van der Velden, M. R. Loken, J. J. M. van Dongen, D. A. Flowers, I. D. Bernstein, and F. R. Appelbaum
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
Blood,
May 15, 2007;
109(10):
4168 - 4170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meshinchi and R. J. Arceci
Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
Oncologist,
March 1, 2007;
12(3):
341 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Chen, J. Wang, K. Hope, L. Jin, J. Dick, R. Cameron, J. Brandwein, M. Minden, and R. M. Reilly
Nuclear Localizing Sequences Promote Nuclear Translocation and Enhance the Radiotoxicity of the Anti-CD33 Monoclonal Antibody HuM195 Labeled with 111In in Human Myeloid Leukemia Cells
J. Nucl. Med.,
May 1, 2006;
47(5):
827 - 836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Taussig, D. J. Pearce, C. Simpson, A. Z. Rohatiner, T. A. Lister, G. Kelly, J. L. Luongo, G.-a. H. Danet-Desnoyers, and D. Bonnet
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
Blood,
December 15, 2005;
106(13):
4086 - 4092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Arceci, J. Sande, B. Lange, K. Shannon, J. Franklin, R. Hutchinson, T. A. Vik, D. Flowers, R. Aplenc, M. S. Berger, et al.
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
Blood,
August 15, 2005;
106(4):
1183 - 1188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Walter, B. W. Raden, D. M. Kamikura, J. A. Cooper, and I. D. Bernstein
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
Blood,
February 1, 2005;
105(3):
1295 - 1302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Z. Lin, M. A. Teitell, and G. J. Schiller
The Evolution of Antibodies into Versatile Tumor-Targeting Agents
Clin. Cancer Res.,
January 1, 2005;
11(1):
129 - 138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mahadevan and A. F. List
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
Blood,
October 1, 2004;
104(7):
1940 - 1951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Walter, B. W. Raden, M. R. Cronk, I. D. Bernstein, F. R. Appelbaum, and D. E. Banker
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
Blood,
June 1, 2004;
103(11):
4276 - 4284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Walter, B. W. Raden, T. C. Hong, D. A. Flowers, I. D. Bernstein, and M. L. Linenberger
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
Blood,
August 15, 2003;
102(4):
1466 - 1473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Amico, A. M. Barbui, E. Erba, A. Rambaldi, M. Introna, and J. Golay
Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3
Blood,
June 1, 2003;
101(11):
4589 - 4597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Estey, P. F. Thall, F. J. Giles, X.-M. Wang, J. E. Cortes, M. Beran, S. A. Pierce, D. A. Thomas, and H. M. Kantarjian
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
Blood,
May 29, 2002;
99(12):
4343 - 4349.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
